This article is a correction to:
A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy
Kun Huang
Fang-Fang Bi
Huan Yang- 1Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- 2Institute of Molecular Precision Medicine and Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital, Central South University, Changsha, China
A Corrigendum on
A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy
by Huang, K., Bi, F.-F., and Yang, H. (2021). Front. Neurol. 12:761636. doi: 10.3389/fneur.2021.761636
In the original article, there was an error. In the Abstract there was a mistake in the statement of the results of the pooled prevalence of congenital myopathy in the all-age population. Instead of “The pooled prevalence of congenital myopathy in the all-age population was 1.50 (95% CI, 0.93–2.06) per 100,000, while the prevalence in the child population was 2.73 (95% CI, 1.34–4.12) per 100,000”, it should be “The pooled prevalence of congenital myopathy in the all-age population was 1.62 (95% CI, 1.13–2.11) per 100,000, while the prevalence in the child population was 2.76 (95% CI, 1.34–4.18) per 100,000.”
A correction has been made to Abstract, Results, Paragraph 1:
Results: A total of 11 studies were included in the systematic review and meta-analysis. Of the 11 studies included, 10 (90.9%) were considered medium-quality, one (9.1%) was considered low-quality, and no study was assessed as having a high overall quality. The pooled prevalence of congenital myopathy in the all-age population was 1.62 (95% CI, 1.13–2.11) per 100,000, while the prevalence in the child population was 2.76 (95% CI, 1.34–4.18) per 100,000. In the pediatric population, the prevalence among males was 2.92 (95% CI, −1.70 to 7.55) per 100,000, while the prevalence among females was 2.47 (95% CI, −1.67 to 6.61) per 100,000. The prevalence estimates of the all-age population per 100,000 were 0.20 (95% CI 0.10–0.35) for nemaline myopathy, 0.37 (95% CI 0.21–0.53) for core myopathy, 0.08 (95% CI −0.01 to 0.18) for centronuclear myopathy, 0.23 (95% CI 0.04–0.42) for congenital fiber-type disproportion myopathy, and 0.34 (95% CI, 0.24–0.44) for unspecified congenital myopathies. In addition, the prevalence estimates of the pediatric population per 100,000 were 0.22 (95% CI 0.03–0.40) for nemaline myopathy, 0.46 (95% CI 0.03–0.90) for core myopathy, 0.44 (95% CI 0.03–0.84) for centronuclear myopathy, 0.25 (95% CI −0.05 to 0.54) for congenital fiber-type disproportion myopathy, and 2.63 (95% CI 1.64–3.62) for unspecified congenital myopathies.
In the original article, there was a mistake in Table 1 as published. The number of cases in the reference Norwood et al. should be 41, not 18. The corrected Table 1 appears below.
TABLE 1
Table 1. Characteristics of the included studies on congenital myopathy prevalence.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
21. Amburgey K, Mcnamara N, Bennett LR, Mccormick ME, Acsadi G, Dowling JJ. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol. (2011) 70:662–5. doi: 10.1002/ana.22510
22. Chung B, Wong V, Ip P. Prevalence of neuromuscular diseases in Chinese children: a study in southern China. J Child Neurol. (2003) 18:217–9. doi: 10.1177/08830738030180030201
23. Dubowitz V. Diagnostic criteria for neuromuscular disorders: Edited by Alan E. H. Emery. Published 1994, European Neuromuscular Centre, Baarn, The Netherlands. ISBN 90 261 0719 6, 72 pp. Neuromuscular Disord. (1994) 4:292–3. doi: 10.1016/0960-8966(94)90038-8
24. World Federation of Neurology Research Committee Research Group on Neuromuscular Diseases. J Neurol Sci. (1988) 86, 333–360.
25. Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. (2000) 10:1–9. doi: 10.1016/S0960-8966(99)00055-3
26. Brooke MH, Carroll JE, Ringel SP. Congenital hypotonia revisited. Muscle Nerve. (1979) 2:84–100. doi: 10.1002/mus.880020203
27. Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord. (1996) 6:69–73. doi: 10.1016/0960-8966(94)00017-4
28. Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. (2017) 88:304–13. doi: 10.1212/WNL.0000000000003504
29. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. (2009) 132:3175–86. doi: 10.1093/brain/awp236
30. Kaplan JC. Gene table of monogenic neuromuscular disorders (nuclear genome only) Vol 19. No 1 January 2009. Neuromuscul Disord. (2009) 19:77–98. doi: 10.1016/j.nmd.2008.11.001
31. Pagola-Lorz I, Vicente E, Ibanez B, Torne L, Elizalde-Beiras I, Garcia-Solaesa V, et al. Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis. (2019) 14:276. doi: 10.1186/s13023-019-1227-x
32. Bonne G, Rivier F, Hamroun D. The 2018 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord. (2017) 27:1152–83. doi: 10.1016/j.nmd.2017.10.005
33. Harris E, Laval S, Hudson J, Barresi R, De Waele L, Straub V, et al. Undiagnosed genetic muscle disease in the north of England: an in depth phenotype analysis. PLoS Curr. (2013) 5:ecurrents.md.37f840ca67f5e722945ecf755f40487e. doi: 10.1371/currents.md.37f840ca67f5e722945ecf755f40487e
34. Santos MA, Fineza I, Moreno T, Cabral P, Ferreira JC, Silva RL, et al. G.P.7 07 Epidemiology of neuromuscular disorders in Portugal at pediatric age. Neuromuscular Disord. (2006) 16:703. doi: 10.1016/j.nmd.2006.05.192
35. Tangsrud SE, Halvorsen S. Child neuromuscular disease in southern Norway. Prevalence, age and distribution of diagnosis with special reference to “non-Duchenne muscular dystrophy”. Clin Genet. (1988) 34:145–52. doi: 10.1111/j.1399-0004.1988.tb02854.x
37. Theadom A, Rodrigues M, Poke G, O'grady G, Love D, Hammond-Tooke G, et al. A Nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology. (2019) 52:128–35. doi: 10.1159/000494115
Keywords: prevalence, congenital myopathy, nemaline myopathy, core myopathy, centronuclear myopathy, congenital fiber-type disproportion myopathy
Citation: Huang K, Bi F-F and Yang H (2022) Corrigendum: A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy. Front. Neurol. 13:857959. doi: 10.3389/fneur.2022.857959
Received: 19 January 2022; Accepted: 19 January 2022;
Published: 14 February 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Huang, Bi and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fang-Fang Bi, fangfangbi@csu.edu.cn; Huan Yang, yangh69@126.com